Rajesh Patel, DO
Family Medicine · Plainfield, NJNPI 1851585863
Payments from drug & device makers
Across 267 payments — averaging $42.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$7K
- Bayer$644
- AstraZeneca$625
- Lilly USA, LLC$592
- Novo Nordisk$389
- Abbott$302
- plus $2K from 24 others
What the payments were for
- Speaking & faculty fees$4,33639%
- Travel & lodging$2,01118%
- Food & beverage$4,87143%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 9 | $6,669 |
| Bayer | 27 | $644 |
| AstraZeneca | 42 | $625 |
| Lilly USA, LLC | 40 | $592 |
| Novo Nordisk | 27 | $389 |
| Abbott | 9 | $302 |
| Boehringer Ingelheim | 18 | $269 |
| Merck | 19 | $264 |
| Johnson & Johnson | 17 | $244 |
| Boston Scientific | 2 | $224 |
| Pfizer | 14 | $200 |
| Exact Sciences | 7 | $173 |
| TELA Bio, Inc. | 1 | $98 |
| AbbVie | 6 | $92 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $73 |
| Novartis | 4 | $55 |
| Amarin Pharma, Inc. | 4 | $53 |
| Amgen | 2 | $37 |
| Daiichi Sankyo Inc. | 2 | $26 |
| Vanda Pharmaceuticals Inc. | 2 | $26 |
| Emmaus Medical, Inc. | 1 | $23 |
| Cequr Corporation | 1 | $22 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Renalytix AI, Inc. | 1 | $17 |
| Bard Peripheral Vascular, Inc. | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| Shield Therapeutics Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G7 GSS (161)$6,347
- WATCHMAN FLX$150
- FREESTYLE LIBRE 3$140
- Kerendia$125
- DEXCOM G6 TRANSMITTER$104
How this compares
$11,231 in reported general payments places this provider in the 95th percentile of 2,084 family medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 296 | $139,598 |
| JardianceEmpagliflozin | 109 | $106,628 |
| MounjaroTirzepatide | 72 | $84,921 |
| JanuviaSitagliptin Phosphate | 70 | $74,386 |
| OzempicSemaglutide | 50 | $65,702 |
| FarxigaDapagliflozin Propanediol | 54 | $60,320 |
| XareltoRivaroxaban | 95 | $40,330 |
| JanumetSitagliptin Phos/Metformin Hcl | 23 | $36,807 |
| TivicayDolutegravir Sodium | 24 | $26,825 |
| TrulicityDulaglutide | 15 | $22,802 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $15,958 |
| TradjentaLinagliptin | 19 | $15,925 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 105 | $14,167 |
| RestasisCyclosporine | 20 | $10,981 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $9,461 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $200 | $139,598296 claims |
| Boehringer IngelheimJardiance, Tradjenta | $269 | $122,552128 claims |
| MerckJanuvia, Janumet, Janumet Xr | $264 | $118,731105 claims |
| Lilly USA, LLCMounjaro, Trulicity | $592 | $107,72387 claims |
| Novo NordiskOzempic | $389 | $65,70250 claims |
| AstraZenecaFarxiga | $625 | $60,32054 claims |
| Johnson & JohnsonXarelto | $244 | $40,33095 claims |
| AbbVieRestasis | $92 | $10,98120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,084 family medicine providers in New Jersey.
Other family medicine in Plainfield
- Howard HassmanClementon$47.1M
- Matthew HongNorth Cape May$15.3M
- Rubaba HussainClark$3.8M
- Gaurang BrahmbhattHoboken$2.6M
- Michael DobrowClifton$2.1M
- Mikhail VarshavskiChatham$1.4M
- Amit BhalodiaCamden$707K
- Jennifer AmicoNew Brunswick$627K
- Janet ColeFar Hills$466K
- Matthew PintoMarlton$239K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.